Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • CAREERS
  • UPDATED WEEKLY

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. The CDMO Framework Winning Business for Adare Pharma Solutions

    3H AGO

    The CDMO Framework Winning Business for Adare Pharma Solutions

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. The CDMO landscape is crowded, fragmented, and increasingly complex. What does it take to stand out and lead in such a competitive space? This week on Making It In Manufacturing, Harry Sloan sat down with Tom Sellig, CEO of Adare Pharma Solutions with a long-standing career spanning commercial leadership, pharma services, and executive roles across global organisations including, Procter and Gamble, Covance, Patheon, LabConnect, and Thermo Fisher Scientific. In this episode, Tom Sellig covers: - How Adare Pharma Solutions positions itself as a technology-driven oral solid dose CDMO with global capabilities across North America and Europe - Why having both US and European manufacturing capabilities is critical for business continuity, regulatory navigation, and client needs in today’s geopolitical environment - The key differentiators behind Adare’s success, including technological breadth, flexibility as a mid-sized CDMO, and the ability to support both large-scale and highly specialised projects - Building a deeply embedded client-centric culture, including company-wide alignment and continuous customer feedback integration For leaders navigating the CDMO and broader Life Sciences manufacturing space, this episode offers a grounded perspective on strategy, growth, and execution. Watch the full conversation for a clear view on what sustainable leadership in this sector really looks like. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Tom Sellig CEO at Adare Pharma Services LinkedIn: https://www.linkedin.com/in/tomsellig/ Harry Sloan BD CDMO Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:20 Overview of Adare Pharma Solutions 01:05 Importance of global footprint in CDMO services 01:45 Key differentiators in a competitive CDMO market 02:43 Client-centric culture and organisational alignment 03:40 Career journey and leadership development 04:25 Lessons from scaling and acquisitions at Patheon 05:05 The Adare framework and company values 05:57 Future outlook for Adare and the CDMO landscape 07:00 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #LifeSciences #PharmaManufacturing #Biopharma #Leadership Hosted on Acast. See acast.com/privacy for more information.

    7 min
  2. Inside the Race to Scale ADCs - Ian Glassford

    5D AGO

    Inside the Race to Scale ADCs - Ian Glassford

    What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing. This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena. In this episode, Ian Glassford covers: • How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00) • Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55) • The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37) • Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11) • Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25) For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry. Follow ARTO: LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Ian Glassford: LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/ Harry Sloan: LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true Timestamps: 00:00 Introduction and live recording from DCAT Week in New York 00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market 01:25 The biggest operational challenges in ADC and AOC manufacturing 02:43 What biotech clients are really looking for beyond technical expertise 03:37 Managing the balance between speed, quality, and execution 04:53 How integrated CDMO and CRO models improve timelines and supply chain control 06:43 The importance of communication and partnership in complex programs 08:11 Ian’s career journey from medicinal chemistry into bio conjugates 10:00 Transitioning from hands-on science into site leadership 10:25 Where Abzena and the wider ADC market are heading in the next five years 11:51 Adapting CDMO models to support evolving biologics modalities 12:29 Closing thoughts #MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates Hosted on Acast. See acast.com/privacy for more information.

    13 min
  3. How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    MAY 5

    How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. How do leading CDMOs move beyond scale to become true strategic partners? This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships. In this episode, John Gagliardi covers: - How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply. - Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies. - What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market. - The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem. - Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility. If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time. Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent John Gagliardi Sales Director at Samsung Biologics LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/ Harry Sloan CDMO BD Lead at ARTO LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D Timestamps: 00:00 Introduction from New York and conference spotlight 00:42 Samsung Biologics as a pure-play CDMO 02:10 Building strategic customer partnerships 03:45 Differentiation beyond standard CDMO models 05:01 Building credibility in ADC manufacturing 07:53 Technical collaboration and winning partnerships 09:07 Lilly Gateway Labs collaboration 11:40 Growth trajectory and future modalities 13:19 Scaling while maintaining quality 15:00 Patient impact and personal motivation 16:35 Closing remarks #MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership Hosted on Acast. See acast.com/privacy for more information.

    17 min
  4. We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang

    APR 28

    We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang

    What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact? This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations. In this episode, Joon Chang covers: • (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites • (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes • (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations • (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking • (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Joon Chang LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction at the DCAT Conference 00:33 Overview of Lotte Biologics and market positioning 01:20 Capabilities in biologics manufacturing and conjugation 02:01 Challenges of entering the CDMO market as a new player 03:05 Importance of talent and retained expertise from legacy sites 03:52 Building relationships with Pharma and biotech clients 04:24 Dual hub model across the US and South Korea 05:01 Manufacturing scale advantages and commercial readiness 06:19 Speed, cost efficiency, and internal tech transfer benefits 07:00 Career journey from Pharma to CDMO leadership 08:04 Understanding client mindset from both Pharma and CDMO perspectives 08:54 Project management experience and client relationship ownership 09:43 Leadership philosophy and full lifecycle thinking 10:10 Building an ideal organisational culture 10:40 Patient-centric approach and ultra-rare disease considerations 11:43 Connecting operations to patient impact 12:34 Applying culture to commercial and sales teams 13:21 Business development mission and value creation 13:40 Leadership approach and empowering teams 15:00 Vision for disrupting the CDMO industry 16:21 Growth, partnerships, and expanding patient reach 17:01 Personal motivation and purpose behind the work 18:00 Team culture and collaboration #MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing Hosted on Acast. See acast.com/privacy for more information.

    18 min
  5. From Lab Scientist to Pharma Leader: 40 Years of Scaling and Strategy Insight - Alison Clayton

    APR 23

    From Lab Scientist to Pharma Leader: 40 Years of Scaling and Strategy Insight - Alison Clayton

    From hands-on pharmacology research to leading strategic projects in advanced manufacturing, this episode explores what it really takes to evolve, adapt, and lead across decades of change in life sciences. This week on Making It In Manufacturing, Harry Sloan sat down with Alison Clayton, Strategic Projects Director at Symbiosis, with over 40 years of experience spanning pharmacology research, pre-clinical and clinical development, and pharmaceutical manufacturing. In this episode, Alison Clayton covers: (00:00) Transitioning from academia into industry and navigating major company acquisitions early in a career (01:40) Moving beyond the lab into strategic, customer-facing roles and discovering a passion for leadership (03:35) Adapting to constant organisational change while maintaining a patient-first mindset (07:26) The risks of scaling too quickly in CDMOs and the importance of realistic capacity and strong partnerships (10:02) Maintaining quality and regulatory standards while growing in a highly competitive pharmaceutical landscape This conversation offers a grounded perspective on long-term career development, leadership in complex environments, and the evolving demands of pharmaceutical manufacturing. If you are building a career in life sciences or scaling within a CDMO environment, this episode provides practical insights worth applying. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Alison Clayton LinkedIn: https://www.linkedin.com/in/alison-clayton-78816711/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction to the episode 00:14 Alison Clayton introduction and career reflection 00:53 Transition from academia to industry 01:15 Experience at Syntex Pharmaceuticals, Roche, and Quintiles 01:40 Moving into strategic and customer-facing roles 02:24 Leadership style shaped by scientific background 02:50 End-to-end experience across drug development 03:13 Navigating challenges and career-defining moments 03:35 Adapting through multiple company transitions 04:24 Balancing commercial goals with patient outcomes 04:56 Experiences in a male-dominated industry 05:51 Advice for women in life sciences leadership 06:09 Career development without a fixed plan 07:00 Balancing career and family life 07:26 Scaling challenges in CDMOs 08:30 Risks of overpromising and underdelivering 09:28 Importance of supply chain and transparency 10:02 Maintaining quality and regulatory compliance 10:27 Overview of Symbiosis 10:57 Market demand for sterile manufacturing 11:20 Scottish identity and company culture 11:39 Differentiation in the CDMO market 12:31 Importance of flexibility and partnerships 13:21 Building long-term client relationships 13:41 Future outlook for Symbiosis 14:05 Evolution of biologics and impact on patients 14:32 Career reflection and delivering medicines to patients 15:17 What excites Alison about the future #MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #LifeSciences #CDMO #Biologics #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.

    16 min
  6. This CDMO Has an Advantage No One Else Can Replicate - Quotient Sciences

    APR 22

    This CDMO Has an Advantage No One Else Can Replicate - Quotient Sciences

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. The CDMO model is evolving fast, but what actually separates the leaders from the rest in today’s market? This week on Making It In Manufacturing, Harry Sloan sat down with Thierry Van Nieuwenhove, CEO of Quotient Sciences, with 25+ years of experience spanning business development, engineering, global manufacturing leadership, and executive roles. In this episode, Thierry covers: • The evolution of the CDMO landscape over 25 years, from API-focused events to a global, multi-disciplinary pharma ecosystem • How Quotient Sciences built a unique translational pharmaceutics platform to combine clinical studies with drug manufacturing, accelerating development timelines by up to 12 months • A career journey from chemical engineering into global business development and leadership, including building manufacturing capabilities in India and working across Europe and the US • Why speed, efficiency, and proof of concept are critical in today’s funding-constrained biotech environment • The growing impact of AI, global innovation shifts including China, and how CDMOs must adapt to remain competitive and support emerging biotech pipelines If you are looking to understand where the CDMO space is heading, and what it takes to lead in a rapidly evolving pharmaceutical market, this episode offers a clear and practical perspective. Be sure to watch the full conversation. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Thierry Van Nieuwenhove CEO at Quotient Sciences LinkedIn: https://www.linkedin.com/in/thierryvan/ Harry Sloan BD CDMO Lead LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction to Making It In Manufacturing at DCAT 00:20 Meet Thierry Van Nieuwenhove, CEO of Quotient Sciences 01:40 Overview of Quotient Sciences and translational pharmaceutics 03:10 Competitive advantage in the CDMO market 04:23 Career journey from engineering to CEO 07:00 Leadership development across global roles 08:18 Operating across international markets and cultures 09:17 Translating early-stage assets into clinical success 12:00 Industry challenges including funding constraints 14:25 AI, partnerships, and innovation in formulation 16:01 Data science and accelerating development timelines 17:32 Global trends including China’s role in innovation 19:56 Strategic adaptation to industry shifts 21:34 Demand for integrated CDMO models 22:55 Customer expectations: speed, excellence, and innovation 25:28 The importance of trust and long-term partnerships #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #Biotech #DrugDevelopment #LifeSciences Hosted on Acast. See acast.com/privacy for more information.

    30 min
  7. The Hidden Challenges of Biologics Development - Dr. Adriana Kiędzierska-Mencfeld

    APR 21

    The Hidden Challenges of Biologics Development - Dr. Adriana Kiędzierska-Mencfeld

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. What does it really take to move from science into CEO leadership while delivering real impact for patients? This week on Making It In Manufacturing, Harry Sloan sat down with Dr Adriana Kiedzierska-Mencfeld, CEO of Rezon Bio, with 20 years of experience spanning biotech, biologics manufacturing, and leadership across industry and scientific roles. In this episode, Dr Adriana Kiedzierska-Mencfeld covers: - Transitioning from academia to industry and the drive to turn science into real patient value - Key leadership moments including entering new technology areas and managing high-pressure decision making - Leading through COVID, maintaining operations, and ensuring both product delivery and team safety - Transforming into a CDMO model and leading organisational change with clarity and purpose - Competing in a crowded CDMO market through cost discipline, quality standards, and operational efficiency If you are working in biotech, manufacturing, or scaling scientific innovation into real-world impact, this conversation offers a clear and grounded perspective on leadership, decision making, and building high-performing teams under pressure. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Dr Adriana Kiedzierska-Mencfeld LinkedIn: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:33 Moving beyond science into leadership 02:06 Career-defining moments and leadership growth 04:56 Leading through COVID and regulatory pressure 06:01 FDA inspection and managing high-stakes environments 07:13 Transition to CDMO and company transformation 09:20 Launch of Resins Bio and stepping into CEO role 11:39 Building trust and delivering for clients 12:29 Cost competitiveness and market positioning 14:20 Speed, quality, and CDMO differentiation 15:22 Market trends and opportunities in biologics 17:33 CDMO positioning and capabilities 18:09 Balancing existing clients and new business 20:08 Personal career journey and challenges 21:44 Advice for women in biotech leadership 22:46 Future of biologics manufacturing 24:33 Motivation and leadership purpose #MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #LifeSciences #ManufacturingLeadership Hosted on Acast. See acast.com/privacy for more information.

    27 min
  8. Why CDMOs Must Scale Smarter - Peter Belden

    APR 16

    Why CDMOs Must Scale Smarter - Peter Belden

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. What does it take to scale pharmaceutical packaging operations globally while maintaining flexibility, quality, and speed to market? In this episode, we explore how strategic packaging partnerships directly impact patient access and commercial success. This week on Making It In Manufacturing, Harry Sloan sat down with Peter Belden, CCO of Tjoapack, with over 25 years of experience spanning outsourced pharmaceutical services across small, mid-sized, and large organisations, primarily within packaging and global supply chain operations. In this episode, Peter Belden covers: 00:00 How pharmaceutical packaging plays a critical role beyond the final step, directly influencing timelines and global market access 01:25 The growing need for late-stage customisation and flexible packaging to meet changing patient demand across multiple markets 02:21 Why successful CDMO partnerships start with deep client understanding, including patient population, dosing, and supply chain needs 03:43 Balancing speed to market with quality through strong planning, collaboration, and supply chain alignment 04:43 Strategic expansion in the US, including facility growth and new packaging lines to support long-term demand This conversation offers a practical look at how packaging strategy, operational discipline, and global experience come together to support pharmaceutical innovation at scale. If you are involved in manufacturing, supply chain, or CDMO partnerships, this episode provides valuable perspective grounded in real industry execution. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Peter Belden LinkedIn: https://www.linkedin.com/in/petersbelden/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:15 Overview of the company and CDMO positioning 01:04 Evolution of pharmaceutical packaging and flexibility 01:48 Late-stage customisation and supply chain adaptability 02:21 Building strong client partnerships in packaging 02:56 Scoping projects and delivering tailored solutions 03:21 Industry change and demand for speed to market 03:43 Balancing quality with responsiveness 04:20 Supply chain collaboration and planning cadence 04:34 US expansion and growth strategy 05:06 Facility expansion and new packaging lines 05:31 Managing growth and operational challenges 06:07 Long-term vision and scaling capabilities 06:50 Career journey into leadership 07:31 International experience and UK market integration 08:39 Adapting to global markets and client needs 09:03 Delivering across 40+ countries 10:05 Motivation and impact on patient access 10:22 Closing remarks #MakingItInManufacturing #ARTOTalent #PharmaManufacturing #CDMO #SupplyChain #Biopharma Hosted on Acast. See acast.com/privacy for more information.

    10 min
See All (31)

About

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Information